Abstracts Archive - Page 207 of 2607 - ACR Meeting Abstracts

Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
James Bistolarides¹, Vidya Sivaraman², Else Bosman³, Linda Wagner-Weiner⁴, Kimberly Morishita⁵, James Nocton¹, Melodee Liegl¹, Amy Pan¹ and David Cabral⁶, and PedVas Investigators Network, ¹Medical College of Wisconsin, Milwaukee, WI, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³UBC, Vancouver, BC, Canada, ⁴University of Chicago, Chicago, IL, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
Abstract Number: PP12 • ACR Convergence 2024
Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care
Sarah Shaw and JP Summers, Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: As someone from the Black, Indigenous, and People of Color (BIPOC) community living with rheumatic conditions, I have experienced firsthand many challenges that people…
Abstract Number: PP15 • ACR Convergence 2024
Breathing Mindfully and How to Control Anxiety in Lupus Patients
Amanda Greene, Lupus Research Alliance, Los Angeles, CA
Background/Purpose: For over four decades, Systemic Lupus Erythematosus has impacted my Quality of Life.. I was diagnosed in 1983- my entire life was changed. I…
Abstract Number: PP14 • ACR Convergence 2024
Support Groups and Chronic Illness: Finding Social Support Among Peers
Alexandra Blumhorst¹ and Estela Mata-Carcamo², ¹Looms for Lupus, Silver Spring, MD, ²Looms for Lupus, Irwindale, CA
Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
Abstract Number: 2589 • ACR Convergence 2024
A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease
Omair Khan¹, Azka Naeem², Kundan Jana², Syed Mujtaba Baqir², Tharun Shyam² and Saumya Nanda², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Rheumatoid Arthritis (RA) and Interstitial Lung Disease (ILD) are systemic inflammatory conditions that independently increase the risk of Acute Coronary Syndrome (ACS). However, there…
Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Eric Roberts¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski⁴, Jing Li⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹University of California, San Francisco, SF, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, ⁴University of California, San Francisco, San Francisco, ⁵University of California, San Francisco, San Francisco, CA, ⁶UCSF / SFVA, San Francisco, CA, ⁷UCSF, San Francisco, CA
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
Abstract Number: 2619 • ACR Convergence 2024
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Tali Eviatar¹, Iftach Sagy², Elad Brav², Amir Bieber³, Victoria Furer⁴ and Ori Elkayam⁵, ¹Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, ²Soroka Medical Cenrter, beer sheva, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
Abstract Number: 2615 • ACR Convergence 2024
Prevalence of and Factors Associated with Developing Long COVID Among Patients with Autoimmune Rheumatic Diseases: A Retrospective Cohort Analysis of National U.S. Data
Namrata Singh¹, Jerrod Anzalone², Lesley Jackson³, Sandra Safo⁴, Zachary Butzin-Dozier⁵, Kaleb Michaud⁶, Holland Stevenson⁶, Maria I. ("Maio") Danila⁷, Jasvinder Singh⁸ and Rena Patel⁹, ¹University of Washington, Bellevue, WA, ²University of Nebraska Medical Center, Omaha, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Minnesota, Minneapolis, MN, ⁵University of California Berkeley School of Public Health, Berkeley, CA, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ⁸Baylor College of Medicine, Birmingham, AL, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Patients with Autoimmune Rheumatic Diseases (AIRDs) are at higher risk of severe COVID-19 outcomes, with greater risk among those with multiple comorbidities, using specific…
Abstract Number: 2590 • ACR Convergence 2024
Pesticide Use and Incident Rheumatoid Arthritis Among Spouses in the Agricultural Health Study: An Updated Analysis
Christine Parks¹, Karen Costenbader², Laura Beane Freeman³, Jonathan Hofmann³ and Dale Sandler⁴, ¹National Institute of Environmental Health Sciences, Epidemiology Branch, Rese, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ³National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, ⁴Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC
Background/Purpose: Systemic autoimmune rheumatic diseases have been associated with farming exposures, but the role of pesticides has not been well studied. The Agricultural Health Study…
Abstract Number: 2587 • ACR Convergence 2024
A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications
Tanishka Agrawal¹, Sumanth Raman², J. Arun³ and HUMEIRA BADSHA⁴, ¹Dubai International Academy, Dubai, Dubai, United Arab Emirates, ²Algorithm Health, Dubai, Dubai, United Arab Emirates, ³Algorithm Health, Dubai, United Arab Emirates, ⁴HBMC, Dubai, United Arab Emirates
Background/Purpose: Patients with chronic autoimmune conditions often need expensive treatments which require prior authorizations by insurance companies. However, significant delays in these processes leave patients…
Abstract Number: 2631 • ACR Convergence 2024
Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study
Pierre Loiseau¹, Aurélie Mailhac², Pierre Duhaut¹, Henrik Toft Sørensen² and Reimar W Thomsen², ¹Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France, ²Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: There is evidence of an increased risk of cardiovascular disease in several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In primary…
Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
April Jorge¹, Aakash Patel¹, Baijun Zhou², Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
Abstract Number: 2453 • ACR Convergence 2024
Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study
Elvira Lesmana¹, Ashley Keehn², Anukul Karn³, Andrea Pauly⁴, Margaret Breen-Lyles², Adam L Edwinson², Madhusudan Grover⁵ and Ashima Makol⁵, ¹Mayo Clinic, Rochester, MN, New York, NY, ²Mayo Clinic, Rochester, MN, Rochester, ³Mayo Clinic, Rochester, MN, Farmington Hills, MI, ⁴Mayo Clinic Rochester, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogeneous, multisystem autoimmune disease with high morbidity and mortality. Gastrointestinal symptoms impact more than 90% of SSc patients,…
Abstract Number: 2610 • ACR Convergence 2024
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Johannes Knitza¹, Johanna Mucke², Manuel Grahammer³, Sebastian Kuhn¹, Nicolas Vuillerme⁴, Felix Muehlensiepen⁵, Gerhard Krönke⁶, Georg Schett⁷, Ann-Christin Pecher⁸ and Martin Krusche⁹, and the TELERA Study Group, ¹Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, ²Heinrich-Heine-University, Duesseldorf, Germany, ³ABATON, Berlin, Germany, ⁴AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, ⁵Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, ⁶Rheumatology, Charité, Berlin, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, ⁹III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
Abstract Number: 2617 • ACR Convergence 2024
Higher Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures, Analysis of Data from 2020 – 2022
Emma Kersey¹, Jing Li², Julia Adler-Milstein³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, ⁴UCSF, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s Rheumatology Informatics System for Effectiveness (RISE) web-based clinician dashboard enables quality performance monitoring and reporting in the Merit-Based Incentive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].